Binding of madindoline A to the extracellular domain of gp130

Biochemistry

Volumn 44, Issue 32, 2005, Pages 10822-10827

  Saleh, Abu Z M ^a   Greenman, Kevin L ^a   Billings, Susan ^a   Van Vranken, David L ^a,b   Krolewski, John J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSENSORS; CELLS; CHEMOTHERAPY; DIMERIZATION; DISEASES; DRUG DOSAGE; ENZYME INHIBITION; GROWTH KINETICS; PRECIPITATION (CHEMICAL); SURFACE PLASMON RESONANCE; TUMORS;

CANCER CACHEXIA; CELL GROWTH; GP130; MADINDOLINE A;

PROTEINS;

3A HYDROXYTETRAHYDROFURO[2,3 B]INDOLE; GLYCOPROTEIN GP 130; INDOLE DERIVATIVE; INTERLEUKIN 11; INTERLEUKIN 6; MADINDOLINE A; NATURAL PRODUCT; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; BINDING AFFINITY; BIOSENSOR; CACHEXIA; CANCER; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIMERIZATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; EMBRYO; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HYPERCALCEMIA; MULTIPLE MYELOMA; PRECIPITATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; STREPTOMYCES; STREPTOMYCES NITROSPOREUS K93 0711; STRUCTURE ANALYSIS; SURFACE PLASMON RESONANCE;

BACTERIAL PROTEINS; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING SITES; CELL LINE, TUMOR; DNA-BINDING PROTEINS; HUMANS; INDOLES; INTERLEUKIN-6; NEURAL CELL ADHESION MOLECULES; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR; SURFACE PLASMON RESONANCE; TRANS-ACTIVATORS;

STREPTOMYCES NITROSPOREUS;

EID: 23844536752     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi050439+     Document Type: Article

References (19)

1. Bazan, J. F. (1990) Structural design and molecular evolution of a cytokine receptor superfamily, Proc. Natl. Acad. Sci. U.S.A. 87, 6934-6938.
2. Boulay, J. L., O'Shea, J. J., and Paul, W. E. (2003) Molecular phylogeny within type I cytokines and their cognate receptors, Immunity 19, 159-163.
3. Heinrich, P. C., Behrmann, I., Haan, S., Hermanns, H. M., Muller-Newen, G., and Schaper, F. (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation, Biochem. J. 374, 1-20.
4. Lutticken, C., Wegenka, U. M., Yuan, J., Buschmann, J., Schindler, C., Ziemiecki, A., Harpur, A. G., Wilks, A. F., Yasukawa, K., Taga, T., Kishimoto, T., Barbieri, G., Pellegrini, S., Sendtner, M., Heinrich, P. C., and Horn, F. (1994) Association of transcription factor APRF and protein kinase JAK1 with the interleukin-6 signal transducer gp130, Science 263, 89-92.
5. Stahl, N., Farruggella, T. J., Boulton, T. G., Zhong, Z., Darnell, J. E., and Yancopoulos, G. D. (1995) Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors, Science 267, 1349-1353.
6. Hirano, T., Ishihara, K., and Hibi, M. (2000) Roles of STAT3 in mediating the cell growth, differentiation and survival signals through the IL-6 family of cytokine receptors, Oncogene 19, 2548-2556.
7. Trikha, M., Corringham, R., Klein, B., and Rossi, J. F. (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence, Clin. Cancer Res. 9, 4653-4665.
8. Nishimoto, N., and Kishimoto, T. (2004) Inhibition of IL-6 for the treatment of inflammatory diseases, Curr. Opin. Pharmacol. 4, 386-391.
9. Omura, S., Hayashi, M., and Tornado, H. (1999) Recent progress of the research on novel microbial metabolites, Pure Appl. Chem. 71, 1673-1681.
10. Hayashi, M., Rho, M. C., Enomoto, A., Fukami, A., Kim, Y. P., Kikuchi, Y., Sunazuka, T., Hirose, T., Komiyama, K., and Omura, S. (2002) Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130, Proc. Natl. Acad. Sci. U.S.A. 99, 14728-14733.
11. McComas, C. C., Perales, J. B., and Van Vranken, D. L. (2002) Synthesis of madindolines and chemical models. Studies of chemical reactivity, Org. Lett. 4, 2337-2340.
12. Kizil, M., Yilmaz, E. I., Pirinccioglu, N., and Aytekin, C. (2003) DNA cleavage activity of diazonium salts: chemical nucleases, Turk. J. Chem. 27, 539-544.
13. Still, W. C., Kahn, M., and Mitra, A. (1978) Rapid chromatographic technique for preparative separations with moderate resolution, J. Org. Chem. 43, 2923-2925.
14. Zettlmeissl, G., Gregersen, J.-P., Duport, J. M., Mehdi, S., Reiner, G., and Seed, B. (1990) Expression and characterization of human CD4: Immunoglobulin fusion protein, DNA Cell Biol. 9, 347-353.
15. Nguyen, V.-P., Saleh, A. Z. M., Arch, A. E., Yan, H., Piazza, F., Kim, J., and Krolewski, J. J. (2002) Stat2 binding to the interferon α receptor 2 (IFNaR2) subunit is not required for interferon-α signaling, J. Biol. Chem. 277, 9713-9721.
16. Boulanger, M. J., Chow, D. C., Brevnova, E. E., and Garcia, K. C. (2003) Hexameric structure and assembly of the interleukin-6/IL-6 α-receptor/ gp130 complex, Science 300, 2101-2104.
17. Timmermann, A., Pflanz, S., Grotzinger, J., Kuster, A., Kurth, L. Pitard, V., Heinrich, P. C., and Muller-Newen, G. (2000) Different epitopes are required for gp130 activation by interleukin-6, oncostatin M and leukemia inhibitory factor, FEBS Lett. 468, 120-124.
18. Hammacher, A., Richardson, R. T., Layton, J. E., Smith, D. K., Angus, L. J., Hilton, D. J., Nicola, N. A., Wijdenes, J., and Simpson, R. J. (1998) The immunoglobulin-like module of gp130 is required for signaling by interleukin-6, but not by leukemia inhibitory factor, J. Biol. Chem. 273, 22701-22707.
19. Boulanger, M. J., Bankovich, A. J., Kortemme, T., Baker, D., and Garcia, K. C. (2003) Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130, Mol. Cell 12, 577-589.